Smarter Compliance Starts with Better Insight 

A curated library of guides, compliance knowledge, and operational insights to help pharmaceutical teams navigate Open Payments reporting, manage HCP events, and streamline field workflows. 
The cannula sets may exhibit a loose connection between the flexible tubing and the nasal cannula resulting in reduced effectiveness and decreased oxygenation.Read more
Date: 2026-10-10
This technical specifications document represents the Food and Drug Administration's (FDA's) current thinking on this topic.Read more
Date: 2026-10-08
Source: FDA - CDER
Table depicting FDA's pediatric product safety communicationsRead more
Date: 2026-10-08
Source: FDA - CDER
On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cRead more
Date: 2026-10-08
Source: FDA - CDER
Haleon is voluntarily recalling eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult to the consumer level. The product is being recalled due to microbial contamination. In immunocompromised individuals, the use of the affected product could potentially resultRead more
Date: 2026-10-08
Source: FDA - CDER
Roche is partnering with Chinese startup Defand Therapeutics to discover new medicines.Read more
Date: 2026-10-08
Overview of the FDA review and approval process for generic drugsRead more
Date: 2026-10-08
Source: FDA - CDER
PhRMA is suing the Trump administration, smaller biotech firms are frustrated over tariffs, and more of the latest pharma news.Read more
Date: 2026-10-08
Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.Read more
Date: 2026-10-08
Source: PharmaVoice
Requirements and Resources for Approved Abbreviated New Drug Applications (ANDAs), including changes to an approved ANDA, postmarketing reporting, promotional materials, annual facility fees, and content of labelingRead more
Date: 2026-10-08
Source: FDA - CDER

Ready to Replace Manual Reconciliation?

Book a Demo